Woodline Partners’s CervoMed CRVO Stock Holding History

Woodline Partners’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-74,852	Closed	-$175K	–	927
2024 Q4	$175K	Buy	+74,852	New	+$728K	﹤0.01%	909

Other funds holding CRVO

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return

AAS

Avantax Advisory Services Dallas, Texas $18.2B AUM 15.06% 1-Year Est. Return

Woodline Partners's CRVO Position: Q1 2025 in Review

Woodline Partners sold out of CervoMed (CRVO) in Q1 2025, closing a stake of 74,852 shares — an estimated $175K sold.

Woodline Partners first reported a position in CRVO in Q4 2024 and held it in 1 quarter. The position peaked at $175K in Q4 2024. 48 funds tracked by Wall St. Rank hold CRVO as of Q1 2025.

Woodline Partners reported no remaining CervoMed position as of Q1 2025 after selling out during the quarter.
Woodline Partners sold 74,852 CervoMed shares in Q1 2025, an estimated $175K.
Woodline Partners first reported a position in CervoMed in Q4 2024 and held it in 1 quarter.
Woodline Partners's CervoMed position peaked at $175K in Q4 2024.
48 funds tracked by Wall St. Rank held CervoMed as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.